PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30129377-2 2018 IBAT inhibitors block ileal absorption of bile acids by: (1) interrupting the enterohepatic circulation of bile resulting in a fall in serum cholesterol and (2) increasing the delivery of bile acids into the colon. Cholesterol 141-152 solute carrier family 10 member 2 Homo sapiens 0-4 33189717-2 2021 Therefore, the regulation and stability of hASBT is vital in maintaining bile acid and cholesterol homeostasis and may serve as a potential target for cholesterol-related disorders. Cholesterol 87-98 solute carrier family 10 member 2 Homo sapiens 43-48 33189717-2 2021 Therefore, the regulation and stability of hASBT is vital in maintaining bile acid and cholesterol homeostasis and may serve as a potential target for cholesterol-related disorders. Cholesterol 151-162 solute carrier family 10 member 2 Homo sapiens 43-48 32201314-3 2020 Therefore, ASBT is considered a favorite target for intervention to regulate the levels of BAs, cholesterol, lipid and glucose etc. Cholesterol 96-107 solute carrier family 10 member 2 Homo sapiens 11-15 31194565-1 2019 The human apical sodium-dependent bile acid transporter (hASBT; SLC10A2) is responsible for the reclamation of bile acids from the intestinal lumen, providing a primary mechanism for bile acid and cholesterol homeostasis. Cholesterol 197-208 solute carrier family 10 member 2 Homo sapiens 57-62 31194565-1 2019 The human apical sodium-dependent bile acid transporter (hASBT; SLC10A2) is responsible for the reclamation of bile acids from the intestinal lumen, providing a primary mechanism for bile acid and cholesterol homeostasis. Cholesterol 197-208 solute carrier family 10 member 2 Homo sapiens 64-71 29304731-2 2018 Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from the liver by reducing recirculation of bile acids (BAs) to the liver, thereby stimulating new BA synthesis from cholesterol. Cholesterol 117-128 solute carrier family 10 member 2 Homo sapiens 0-45 29304731-2 2018 Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from the liver by reducing recirculation of bile acids (BAs) to the liver, thereby stimulating new BA synthesis from cholesterol. Cholesterol 246-257 solute carrier family 10 member 2 Homo sapiens 0-45 29304731-2 2018 Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from the liver by reducing recirculation of bile acids (BAs) to the liver, thereby stimulating new BA synthesis from cholesterol. Cholesterol 246-257 solute carrier family 10 member 2 Homo sapiens 47-51 29198943-1 2018 The human apical sodium-dependent bile acid transporter, hASBT/SLC10A2, plays a central role in cholesterol homeostasis via the efficient reabsorption of bile acids from the distal ileum. Cholesterol 96-107 solute carrier family 10 member 2 Homo sapiens 57-62 29198943-1 2018 The human apical sodium-dependent bile acid transporter, hASBT/SLC10A2, plays a central role in cholesterol homeostasis via the efficient reabsorption of bile acids from the distal ileum. Cholesterol 96-107 solute carrier family 10 member 2 Homo sapiens 63-70 29304731-2 2018 Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from the liver by reducing recirculation of bile acids (BAs) to the liver, thereby stimulating new BA synthesis from cholesterol. Cholesterol 117-128 solute carrier family 10 member 2 Homo sapiens 47-51 28336180-0 2017 An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis: The apical sodium-dependent bile acid transporter (SLC10A2/ASBT). Cholesterol 99-110 solute carrier family 10 member 2 Homo sapiens 175-182 28336180-0 2017 An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis: The apical sodium-dependent bile acid transporter (SLC10A2/ASBT). Cholesterol 99-110 solute carrier family 10 member 2 Homo sapiens 183-187 28336180-3 2017 Previous studies revealed that regulation of the ASBT involves BAs and cholesterol. Cholesterol 71-82 solute carrier family 10 member 2 Homo sapiens 49-53 28336180-4 2017 In addition, abnormal ASBT expression and function might lead to some diseases associated with disorders in the enterohepatic circulation of BAs and cholesterol homeostasis, such as diarrhoea and gallstones. Cholesterol 149-160 solute carrier family 10 member 2 Homo sapiens 22-26 28336180-5 2017 However, decreasing cholesterol or BAs by partly inhibiting ASBT-mediated transport might be used for treatments of hypercholesterolemia, cholestasis and diabetes. Cholesterol 20-31 solute carrier family 10 member 2 Homo sapiens 60-64 28336180-6 2017 This review mainly discusses the regulation of the ASBT by BAs and cholesterol and its relevance to diseases and treatment. Cholesterol 67-78 solute carrier family 10 member 2 Homo sapiens 51-55 24045943-1 2013 Human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) is responsible for intestinal reabsorption of bile acids and plays a key role in cholesterol homeostasis. Cholesterol 150-161 solute carrier family 10 member 2 Homo sapiens 53-58 28303230-2 2017 Inhibition of ASBT could increase the excretion of bile acids, thus increasing bile acid synthesis and consequently cholesterol consumption. Cholesterol 116-127 solute carrier family 10 member 2 Homo sapiens 14-18 28303230-3 2017 Therefore, ASBT is an attractive target for developing new cholesterol-lowering drugs. Cholesterol 59-70 solute carrier family 10 member 2 Homo sapiens 11-15 25855079-2 2015 Inhibiting ASBT function and bile acid absorption is an attractive approach to lower plasma cholesterol and improve glucose imbalance in diabetic patients. Cholesterol 92-103 solute carrier family 10 member 2 Homo sapiens 11-15 24498857-2 2014 ASBT inhibitors reportedly lower plasma triglyceride levels and increase HDL (high-density lipoprotein) cholesterol levels. Cholesterol 104-115 solute carrier family 10 member 2 Homo sapiens 0-4 24498857-4 2014 In the present study, we investigated the possible involvement of ASBT in RSV-mediated cholesterol-lowering effects. Cholesterol 87-98 solute carrier family 10 member 2 Homo sapiens 66-70 24498857-12 2014 We conclude that regulation of ASBT expression by RSV may have clinical relevance with regard to the observed cholesterol-lowering effects of RSV. Cholesterol 110-121 solute carrier family 10 member 2 Homo sapiens 31-35 24317697-4 2014 In recent years, ASBT has attracted much interest as a potential drug target for treatment of hypercholesterolaemia, because inhibition of ASBT reduces reabsorption of bile acids, thus increasing bile acid synthesis and consequently cholesterol consumption. Cholesterol 99-110 solute carrier family 10 member 2 Homo sapiens 17-21 24317697-4 2014 In recent years, ASBT has attracted much interest as a potential drug target for treatment of hypercholesterolaemia, because inhibition of ASBT reduces reabsorption of bile acids, thus increasing bile acid synthesis and consequently cholesterol consumption. Cholesterol 99-110 solute carrier family 10 member 2 Homo sapiens 139-143 24045943-1 2013 Human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) is responsible for intestinal reabsorption of bile acids and plays a key role in cholesterol homeostasis. Cholesterol 150-161 solute carrier family 10 member 2 Homo sapiens 60-67 18063707-8 2008 Our study illustrates that cholesterol content of lipid rafts is essential for the optimal activity of ASBT and support the association of ASBT with lipid rafts. Cholesterol 27-38 solute carrier family 10 member 2 Homo sapiens 139-143 23815591-1 2013 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2), primarily expressed in the ileum, is involved in both the recycling of bile acids and cholesterol homeostasis. Cholesterol 160-171 solute carrier family 10 member 2 Homo sapiens 57-62 23815591-1 2013 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2), primarily expressed in the ileum, is involved in both the recycling of bile acids and cholesterol homeostasis. Cholesterol 160-171 solute carrier family 10 member 2 Homo sapiens 64-71 23678871-2 2013 Multiple pharmaceutical companies have exploited the physiological link between ASBT and hepatic cholesterol metabolism, which led to the clinical investigation of ASBT inhibitors as lipid-lowering agents. Cholesterol 97-108 solute carrier family 10 member 2 Homo sapiens 80-84 23678871-2 2013 Multiple pharmaceutical companies have exploited the physiological link between ASBT and hepatic cholesterol metabolism, which led to the clinical investigation of ASBT inhibitors as lipid-lowering agents. Cholesterol 97-108 solute carrier family 10 member 2 Homo sapiens 164-168 23752471-2 2013 Inhibition of ASBT would reduce bile acid pool size and lower cholesterol levels. Cholesterol 62-73 solute carrier family 10 member 2 Homo sapiens 14-18 21976025-4 2011 It has been shown in animal models that plasma cholesterol levels are considerably lowered by specific inhibitors of ASBT, and ASBT is thus a target for hypercholesterolaemia drugs. Cholesterol 47-58 solute carrier family 10 member 2 Homo sapiens 117-121 21646357-1 2011 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) plays a critical role in the enterohepatic circulation of bile acids, as well as in cholesterol homeostasis. Cholesterol 157-168 solute carrier family 10 member 2 Homo sapiens 57-62 21646357-1 2011 The human apical sodium-dependent bile acid transporter (hASBT, SLC10A2) plays a critical role in the enterohepatic circulation of bile acids, as well as in cholesterol homeostasis. Cholesterol 157-168 solute carrier family 10 member 2 Homo sapiens 64-71 18063707-9 2008 These findings suggest a novel mechanism by which ASBT activity may be rapidly modulated by alterations in cholesterol content of plasma membrane and thus have important implications in processes related to maintenance of bile acid and cholesterol homeostasis. Cholesterol 107-118 solute carrier family 10 member 2 Homo sapiens 50-54 18063707-9 2008 These findings suggest a novel mechanism by which ASBT activity may be rapidly modulated by alterations in cholesterol content of plasma membrane and thus have important implications in processes related to maintenance of bile acid and cholesterol homeostasis. Cholesterol 236-247 solute carrier family 10 member 2 Homo sapiens 50-54 15350125-1 2004 The apical sodium-dependent bile acid transporter (ASBT, SLC10A2) facilitates the enterohepatic circulation of bile salts and plays a key role in cholesterol metabolism. Cholesterol 146-157 solute carrier family 10 member 2 Homo sapiens 4-49 16134950-2 2005 We believe that by preventing the reabsorption of bile acids, a minimally absorbed apical sodium-codependent bile acid transporter (ASBT) inhibitor would lower the serum cholesterol without the potential systemic side effects of an absorbed drug. Cholesterol 170-181 solute carrier family 10 member 2 Homo sapiens 132-136 18063707-0 2008 Modulation of ileal bile acid transporter (ASBT) activity by depletion of plasma membrane cholesterol: association with lipid rafts. Cholesterol 90-101 solute carrier family 10 member 2 Homo sapiens 43-47 18063707-2 2008 To gain insight into the cellular regulation of ASBT, we investigated the association of ASBT with cholesterol and sphingolipid-enriched specialized plasma membrane microdomains known as lipid rafts and examined the role of membrane cholesterol in maintaining ASBT function. Cholesterol 99-110 solute carrier family 10 member 2 Homo sapiens 89-93 18063707-2 2008 To gain insight into the cellular regulation of ASBT, we investigated the association of ASBT with cholesterol and sphingolipid-enriched specialized plasma membrane microdomains known as lipid rafts and examined the role of membrane cholesterol in maintaining ASBT function. Cholesterol 99-110 solute carrier family 10 member 2 Homo sapiens 89-93 18063707-5 2008 Disruption of lipid rafts by depletion of membrane cholesterol with methyl-beta-cyclodextrin (MbetaCD) significantly reduced the association of ASBT with lipid rafts, which was paralleled by a decrease in ASBT activity in Caco-2 and HEK-293 cells treated with MbetaCD. Cholesterol 51-62 solute carrier family 10 member 2 Homo sapiens 144-148 18063707-8 2008 Our study illustrates that cholesterol content of lipid rafts is essential for the optimal activity of ASBT and support the association of ASBT with lipid rafts. Cholesterol 27-38 solute carrier family 10 member 2 Homo sapiens 103-107 16484503-0 2006 Cholesterol dependent downregulation of mouse and human apical sodium dependent bile acid transporter (ASBT) gene expression: molecular mechanism and physiological consequences. Cholesterol 0-11 solute carrier family 10 member 2 Homo sapiens 56-101 16484503-0 2006 Cholesterol dependent downregulation of mouse and human apical sodium dependent bile acid transporter (ASBT) gene expression: molecular mechanism and physiological consequences. Cholesterol 0-11 solute carrier family 10 member 2 Homo sapiens 103-107 16541252-10 2006 Based on the high structural homology between ASBT and SOAT, pharmacological inhibitors of the ASBT, which are currently being tested in clinical trials for cholesterol-lowering therapy, should be evaluated for their cross-reactivity with SOAT. Cholesterol 157-168 solute carrier family 10 member 2 Homo sapiens 95-99 15604201-2 2005 ASBT function is essential for maintenance of cholesterol homeostasis in the body. Cholesterol 46-57 solute carrier family 10 member 2 Homo sapiens 0-4 15604201-3 2005 The molecular mechanisms of the direct effect of cholesterol on human ASBT function and expression are not entirely understood. Cholesterol 49-60 solute carrier family 10 member 2 Homo sapiens 70-74 15604201-4 2005 The present studies were undertaken to establish a suitable in vitro experimental model to study human ASBT function and its regulation by cholesterol. Cholesterol 139-150 solute carrier family 10 member 2 Homo sapiens 103-107 15604201-13 2005 These data provide novel evidence for the direct regulation of human ASBT function by cholesterol and suggest that this phenomenon may play a central role in cholesterol homeostasis. Cholesterol 86-97 solute carrier family 10 member 2 Homo sapiens 69-73 15604201-13 2005 These data provide novel evidence for the direct regulation of human ASBT function by cholesterol and suggest that this phenomenon may play a central role in cholesterol homeostasis. Cholesterol 158-169 solute carrier family 10 member 2 Homo sapiens 69-73 15350125-1 2004 The apical sodium-dependent bile acid transporter (ASBT, SLC10A2) facilitates the enterohepatic circulation of bile salts and plays a key role in cholesterol metabolism. Cholesterol 146-157 solute carrier family 10 member 2 Homo sapiens 51-55 15350125-1 2004 The apical sodium-dependent bile acid transporter (ASBT, SLC10A2) facilitates the enterohepatic circulation of bile salts and plays a key role in cholesterol metabolism. Cholesterol 146-157 solute carrier family 10 member 2 Homo sapiens 57-64 12819193-2 2003 In patients with primary bile acid malabsorption, mutations in the ileal bile acid transporter gene (Slc10a2) lead to congenital diarrhea, steatorrhea, and reduced plasma cholesterol levels. Cholesterol 171-182 solute carrier family 10 member 2 Homo sapiens 101-108 12562847-1 2003 Discovery of the ileal apical sodium-dependent bile acid transporter (ASBT) permitted development of specific inhibitors of bile acid reabsorption, potentially a new class of cholesterol-lowering agents. Cholesterol 175-186 solute carrier family 10 member 2 Homo sapiens 23-68 12562847-1 2003 Discovery of the ileal apical sodium-dependent bile acid transporter (ASBT) permitted development of specific inhibitors of bile acid reabsorption, potentially a new class of cholesterol-lowering agents. Cholesterol 175-186 solute carrier family 10 member 2 Homo sapiens 70-74 12177176-8 2002 In conclusion, 264W94 is a potent new cholesterol lowering agent that acts through inhibition of IBAT and exhibits activity in a human model. Cholesterol 38-49 solute carrier family 10 member 2 Homo sapiens 97-101 12475240-1 2002 Drug intervention that prevents reabsorption of circulating bile acids by the apical (ileal) sodium/bile acid cotransporter (ASBT) may be a promising new therapy for lowering of plasma cholesterol. Cholesterol 185-196 solute carrier family 10 member 2 Homo sapiens 125-129 34346218-1 2021 Inhibiting apical sodium-dependent bile acid transporter (ASBT) has been identified as a potential strategy to reduce plasma cholesterol levels. Cholesterol 125-136 solute carrier family 10 member 2 Homo sapiens 11-56 9109432-1 1997 Primary bile acid malabsorption (PBAM) is an idiopathic intestinal disorder associated with congenital diarrhea, steatorrhea, interruption of the enterohepatic circulation of bile acids, and reduced plasma cholesterol levels. Cholesterol 206-217 solute carrier family 10 member 2 Homo sapiens 33-37 11808323-3 2002 Inhibition of IBAT by specific IBAT inhibitors such as S-8921 has been proven to lower serum cholesterol in a variety of experimental animals. Cholesterol 93-104 solute carrier family 10 member 2 Homo sapiens 14-18 11808323-3 2002 Inhibition of IBAT by specific IBAT inhibitors such as S-8921 has been proven to lower serum cholesterol in a variety of experimental animals. Cholesterol 93-104 solute carrier family 10 member 2 Homo sapiens 31-35 34346218-1 2021 Inhibiting apical sodium-dependent bile acid transporter (ASBT) has been identified as a potential strategy to reduce plasma cholesterol levels. Cholesterol 125-136 solute carrier family 10 member 2 Homo sapiens 58-62